Open AccessHedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis
Author(s) -
Wenzhen Ge,
Chieh-I Chen,
Ning Wu,
Matthew G. Fury,
Emily S. Ruiz,
Jessica J. Jalbert
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0373
Subject(s) - medicine , basal cell carcinoma , hedgehog signaling pathway , hedgehog , vismodegib , oncology , cancer research , basal cell , signal transduction , microbiology and biotechnology , biology
Aims: To examine real-world treatment patterns for Hedgehog pathway inhibitors (HHIs) for the treatment of advanced basal cell carcinoma. Patients & methods: HHI initiators between January 2013 and June 2019 were identified from IBM MarketScan ® claims data. Time to treatment discontinuation and reinitiation were estimated using Kaplan-Meier methods using a 60-day grace period. Results: Among 526 patients with basal cell carcinoma who initiated an HHI, median time to first discontinuation was 144 days, and risk of discontinuation by 12 months was 88.0%. Probability of reinitiation within 12 months was 19.7%, and median time to second discontinuation was 118 days. Conclusion: HHI discontinuation was common and reinitiation uncommon in clinical practice. Future research should evaluate persistence with recently approved therapies.